Von Der Leyen: Pfizer to Boost Q2 EU Vaccine Supply by 50M

The transcript discusses the challenges in vaccine delivery and the importance of swift action to support Europe's vaccination rollout. An agreement with Biotech Pfizer has been reached to accelerate the delivery of 50 million additional doses, initially planned for the fourth quarter of 2021, now available in the second quarter. This will bring the total to 250 million doses, distributed among Member States, aiding the vaccination campaigns.

What is a key factor that can affect the planned delivery schedules of vaccines?

• Manufacturers

• Public demand

• Weather conditions

• Government policies

What is the main purpose of the agreement with Biotech Pfizer?

• To develop a new vaccine

• To increase vaccine prices

• To speed up vaccine delivery

• To reduce vaccine side effects

How many additional doses of Biotech Pfizer vaccines will be delivered in the second quarter of 2021?

• 100 million

• 50 million

• 25 million

• 10 million

In which quarter were the additional 50 million doses initially planned for delivery?

• Fourth quarter of 2021

• Third quarter of 2021

• Second quarter of 2021

• First quarter of 2021

How will the additional doses be distributed among the Member States?

• Random selection

• First come, first served

• Pro rata population

• Based on economic status